Sector News

Roche Diagnostics head Roland Diggelmann to step down

August 28, 2018
Life sciences

The leader of Roche’s diagnostics division, Roland Diggelmann, announced plans to leave the company, effective Sept. 30.

Michael Heuer, Roche Diagnostics’ region head for Europe, Middle East, Africa and Latin America, will take over until a successor is named, and will also take Digglemann’s spot on the company’s corporate executive committee.

The diagnostics division accounted for nearly a quarter of Roche’s sales in 2017, gathering about 12.1 billion Swiss francs ($12.4 billion), with immunotherapy diagnostics being a leading contributor to its 5% growth, especially in centralized and point-of-care solutions. The division’s marketing and distribution also increased that year, with higher spending in emerging markets such as China.

In a statement, Roche CEO Severin Schwan, himself a veteran of the diagnostics division, thanked Digglemann for his contributions during his 10 years at the company, and described Heuer as a respected leader with a wealth of experience in diagnostics.

Diggelmann began at Roche in 2008, and previously served as region head of Asia Pacific for Roche Diagnostics before being named chief in 2012—when the Swiss giant’s pharma COO Pascal Soriot took a new job at AstraZeneca, causing then-diagnostics COO Daniel O’Day to take his place. Later that year, Roche broke ground for a $300 million expansion of its diagnostics headquarters in Indianapolis.

Prior to Roche, Diggelmann worked in sales and marketing for Sulzer Medica/Centerpulse and Zimmer.

Heuer joined Boehringer Mannheim in 1983 and, following Roche’s acquisition in 1998, was appointed to his current role in 2008. He has held various leadership roles in sales, marketing and product development in Germany, Austria and the U.S.

By Conor Hale

Source: Fierce Biotech

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.